GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront. The new deal – ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results